Overall Fundamental outlook

*JUBLPHARMA makes the list of companies with the worst technicals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

Investors may be wary of JUBLPHARMA as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 23.228182
debtToEquity 43.776000
earningsGrowth -0.787000
revenueGrowth 0.098000
grossMargins 0.679410
operatingMargins 0.100750
trailingEps 28.980000
forwardEps 0.000000

JUBLPHARMA's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
JUBLPHARMA's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that JUBLPHARMA might struggle to maintain its current profit levels.
Jubilant Pharmova Limited's negative gross and operating margins point to losses in both production and operations. This suggests the company is facing financial challenges and may need to address cost management or improve revenue generation.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

The steady upward revision of JUBLPHARMA's price projections indicates growing confidence in the company's performance. Analysts are becoming increasingly optimistic about JUBLPHARMA's future prospects and potential for growth.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


JUBLPHARMA had 1 buy transactions, with market price of 1219.5999755859375.There were no buy transactions during the period under consideration.With more selling than buying at JUBLPHARMA's current price levels, there is a risk of further price decline. If this trend continues, it may suggest investor pessimism, leading to a continued downward trajectory for the stock.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


A recent buy bias from analysts toward Jubilant Pharmova Limited indicates strong confidence in the stock's future performance. This could encourage investors to park their money in Jubilant Pharmova Limited, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.